Pharmaceuticals

Telehealth firms now offer needle-free weight-loss pills. As companies like FitRx expand access, they enter a regulatory minefield of unapproved drugs.

Early trial data for Verastem Oncology's VS-7375 reveals significant anti-tumor activity and a good safety profile, igniting hope for tough-to-treat cancers.

New telehealth platforms promise to unlock Zepbound by navigating insurance mazes. But are they building a safe superhighway or a risky digital backroad?

A new €35,000 grant fuels Canadian gut health research, highlighting a strategic play where corporate philanthropy meets a multi-billion dollar market.

A new report shows AI directs 80% of aesthetic medicine searches to AbbVie & Galderma, creating a 'visibility gap' that leaves 11,500 small clinics invisible.

A new book on psilocybin therapy for women signals a strategic shift from clinical data to lived experience, building a new market in the wellness economy.

A landmark partnership between Merck and Mae aims to professionalize the doula workforce, using tech to fight deep-seated maternal health disparities.

With a $2.74M grant from The Michael J. Fox Foundation, biotech startup X-tosis is advancing a novel therapy that aims to fix the cell's failing powerhouses.

Decades-old treatments for bladder cancer are failing. Now, a wave of gene and viral therapies is sparking a market revolution and offering new hope.

With a key grant from Breakthrough T1D, MannKind aims its inhaled insulin at children. Is this a life-changing innovation or a high-stakes corporate revival?

Eli Lilly's partnership with ŌURA isn't just a perk. It's a strategic move to solve the GLP-1 adherence problem and build a data-driven moat in a $100B market.

Quoin Pharma's new drug name is a key step, but the path to the first-ever treatment for a rare skin disease reveals the complex interplay of innovation and finance.

SRX Global's investment in ARMR Sciences' long-lasting fentanyl countermeasure signals a paradigm shift from reactive treatment to proactive biodefense.

Haisco's massive licensing deal with Nuvectis for two high-potential drugs isn't just a transaction; it's a signal of a new world order in biotech.

The Oklahoma CDMO's move to integrate AI and 'high-touch' service isn't just a website refresh; it's a strategic play in a multi-billion dollar market.

Illumina's appointment of Eli Lilly's R&D chief isn't just a new hire; it's a strategic masterstroke signaling a deeper push into drug development.

With a novel nasal spray targeting the host, not the virus, RA Capital-backed NorthLinks Bio aims to create a broad-spectrum defense against respiratory threats.

Kalaris Therapeutics, backed by VEGF pioneer Dr. Napoleone Ferrara, presents early data on its next-gen eye drug. Can TH103's novel science overcome recent development hurdles?

BioMendics secured a key FDA Fast Track designation for its EBS therapy, a strategic move that de-risks development and signals a new era for rare disease treatment.

Amid crushing industry pressures, McKesson's ideaShare event reveals a strategic blueprint: leveraging AI and advocacy to keep independent pharmacies alive.